MedPath

To study the local application effect of Liquid Mixture containing Manjishtha (Rubia cordifolia Linn.) Extract In the Treatment of Dry Eczema

Not Applicable
Conditions
Health Condition 1: L20-L30- Dermatitis and eczema
Registration Number
CTRI/2023/01/049126
Lead Sponsor
Mrs Hema Vishal Nalamwar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Adult male or female patient diagnosed with dry eczema. ( 30 to 60 yrs)

2) Adult male or female patient diagnosed with dry eczema and not treated with any oral or external medicine in past 15 days before recruitment (if the patient is on any other oral or external medicine it shall be stopped for 15 days then the treatment which is subject matter of this study shall begin).

3) Individuals willing to sign informed consent.

Exclusion Criteria

1) Individuals allergic to manjishtha or allergic to any pharmaceutical excipient.

2) Individuals suffering from serious neurological defects, skin cancer, immunodeficiency, bullous skin disease, aplasia, albinism, weeping lesions and very severe cases (it means extensively spread lesions and not refers to signs of individual lesion).

3) Individuals not willing to sign informed consent.

4) Individuals currently participating in any other clinical study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To find out effectiveness of external application of liquid mixture extract of Manjishtha and pharmaceutical excipients on EASI score (Eczema Area and Severity Index score) in the treatment of Dry Eczema for 30 days.Timepoint: at baseline, 10 days, 20 days and 30 days
Secondary Outcome Measures
NameTimeMethod
To find out effectiveness of external application of liquid mixture containing Manjishtha Extract and pharmaceutical excipients on Improvement of Quality of Life by using Questionnaire in the treatment of Dry Eczema for 30 days.Timepoint: at base line, 10 days, 20 days and 30 days
© Copyright 2025. All Rights Reserved by MedPath